BLA 103132 · Schering
Intron A
Interferon Alfa-2b
NovelLast checked: Nov 20, 2026Latest source record: Nov 26, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1986
Jun 4, 1986
Approved uses
8
Original approval plus efficacy supplements
Registered trials
395
118 Phase 3, 10 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 21, 2001 Supplement 1144 · Efficacy
- Aug 18, 1998 Supplement 1127 · Efficacy
- Nov 6, 1997 Supplement 1116 · Efficacy · priority review ReviewLetterLabel
- Mar 26, 1997 Supplement 1107 · Efficacy
- Dec 5, 1995 Supplement 1096 · Efficacy
- May 14, 1993 Supplement 1040 · Efficacy
- Jul 13, 1992 Supplement 1030 · Efficacy
- Jun 4, 1986 Original approval · Type 1 - New Molecular Entity Review
3 products under this application
- INTRON A · INTERFERON ALFA-2B 25MIU/VIAL · VIAL, · Prescription
- INTRON A · INTERFERON ALFA-2B 10MIU/VIAL · VIAL, · Prescription
- INTRON A · INTERFERON ALFA-2B 18MIU/VIAL · VIAL, · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Interferon Alfa-2b" as an intervention, any sponsor and status, largest first.
- Comparison of PEG-Intron and Two Different Doses of Ribavirin for the Treatment of Chronic Hepatitis C In Treatment Naïve SubjectsPivotal-lookingCompleted
Weill Medical College of Cornell UniversityAcademic, hospital or other
NCT00299936 · 5,000 participants
Drug: Ribavirin, PEG-Intron · For: Chronic Hepatitis C
- Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00081770 · 4,469 participants · Start Mar 2004 · Primary completion Nov 2007
Drug: PegIntron (peginterferon alfa-2b; SCH 54031); PegIntron (peginterferon alfa-2b; SCH 54031) and 3 more · For: Hepatitis C, Chronic
- Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node MetastasisPivotal-lookingCompleted
University of Alabama at BirminghamAcademic, hospital or other
NCT00004196 · 3,000 participants (planned) · Start Oct 1999 · Primary completion Oct 2004
Drug: recombinant interferon alfa; Observation · For: Melanoma (Skin)
Sites: Birmingham, Alabama; Louisville, Kentucky; New Brunswick, New Jersey · 4 sites in all
- PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00039871 · 2,333 participants · Start May 2002 · Primary completion Sep 2007
Drug: PegIntron (peginterferon alfa-2b; SCH 54031); REBETOL (ribavirin; SCH 18908) · For: Hepatitis; Hepatitis C, Chronic; Fibrosis and 1 more
- Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)Pivotal-lookingTerminated
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00689390 · 1,954 participants · Start Feb 20, 2007 · Primary completion Oct 13, 2014
Drug: Boceprevir; Narlaprevir and 2 more · For: Hepatitis C, Chronic; Hepacivirus
- The Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolPivotal-lookingCompleted
The Camelot FoundationAcademic, hospital or other
NCT04349410 · 1,800 participants · Start Apr 11, 2020 · Primary completion Sep 14, 2020
Drug: Hydroxychloroquine, Azithromycin; Hydroxychloroquine, Doxycycline and 9 more · For: CoVid 19 Positive
Sites: Los Angeles, California
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by SurgeryPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT01274338 · 1,673 participants · Start Jun 17, 2011 · Primary completion Feb 15, 2019
Drug: Ipilimumab; Recombinant Interferon Alfa-2b · For: Melanoma of Unknown Primary; Recurrent Melanoma; Stage IIIB Cutaneous Melanoma AJCC v7 and 2 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 937 sites in all
- Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00265395 · 1,428 participants · Start Dec 2004 · Primary completion May 2008
Drug: Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®); Combination of pegylated interferon alfa-2b and ribavirin · For: Hepatitis C, Chronic
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
Boorjian SA, Alemozaffar M, Konety BR, et al. · Lancet Oncol 2021 · Clinical Trial, Phase III, Multicenter Study
- Clinical Trial of High-Dose Pegylated-Interferon-Alfa-2b Combined With Phototherapy in Advanced Stage Mycosis Fungoides.
Walker CJ, Espinosa ML, Mehta-Shah N, et al. · J Drugs Dermatol 2021 · Clinical Trial
- Topical pharmacotherapy for ocular surface squamous neoplasia: systematic review and meta-analysis.
Kozma K, Dömötör ZR, Csutak A, et al. · Sci Rep 2022 · Meta-Analysis, Systematic Review
- Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials.
Carithers RL, Emerson SS · Hepatology 1997 · Meta-Analysis
- Overview of preclinical and clinical studies of interferon alfa-2b in combination with cytotoxic drugs.
Welander CE · Invest New Drugs 1987 · Clinical Trial, Review
- Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609.
McLouth LE, Zheng Y, Smith S, et al. · Qual Life Res 2023 · Clinical Trial, Phase III
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.